About Solute carrier family 60 member 1
Solute carrier family 60 member 1 (SLC60A1) is a protein
from Homo sapiens identified by UniProt accession
Q8N468, 514 residues long.
MolForge cross-references it against 0 known binders and
41 disease associations.
Target properties
| Protein name | Solute carrier family 60 member 1 |
| UniProt accession | Q8N468 |
| Gene | SLC60A1 |
| Organism | Homo sapiens |
| Length | 514 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (41)
Diseases linked to this target (Open Targets).
- glomerular filtration rate · score 0.24
- leukocyte count · score 0.21
- creatinine measurement · score 0.19
- papillary thyroid carcinoma · score 0.07
- neoplasm · score 0.04
- clear cell renal carcinoma · score 0.04
- gastric carcinoma · score 0.04
- glioblastoma multiforme · score 0.04
- astrocytoma · score 0.04
- gonorrhea · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N468-F1 | alphafold | PREDICTED | 77.20 | — |
Amino-acid sequence (514 residues)
MGCDGRVSGL LRRNLQPTLT YWSVFFSFGL CIAFLGPTLL DLRCQTHSSL PQISWVFFSQ QLCLLLGSAL GGVFKRTLAQ SLWALFTSSL AISLVFAVIP FCRDVKVLAS VMALAGLAMG CIDTVANMQL VRMYQKDSAV FLQVLHFFVG FGALLSPLIA DPFLSEANCL PANSTANTTS RGHLFHVSRV LGQHHVDAKP WSNQTFPGLT PKDGAGTRVS YAFWIMALIN LPVPMAVLML LSKERLLTCC PQRRPLLLSA DELALETQPP EKEDASSLPP KFQSHLGHED LFSCCQRKNL RGAPYSFFAI HITGALVLFM TDGLTGAYSA FVYSYAVEKP LSVGHKVAGY LPSLFWGFIT LGRLLSIPIS SRMKPATMVF INVVGVVVTF LVLLIFSYNV VFLFVGTASL GLFLSSTFPS MLAYTEDSLQ YKGCATTVLV TGAGVGEMVL QMLVGSIFQA QGSYSFLVCG VIFGCLAFTF YILLLFFHRM HPGLPSVPTQ DRSIGMENSE CYQR
Explore Solute carrier family 60 member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets